stoxline Quote Chart Rank Option Currency Glossary
  
Profound Medical Corp. (PROF)
6.38  -0.21 (-3.19%)    11-20 16:00
Open: 6.535
High: 6.65
Volume: 144,188
  
Pre. Close: 6.59
Low: 6.29
Market Cap: 234(M)
Technical analysis
2026-11-20 4:47:11 PM
Short term     
Mid term     
Targets 6-month :  8.23 1-year :  9.39
Resists First :  7.05 Second :  8.03
Pivot price 7.13
Supports First :  5.44 Second :  4.53
MAs MA(5) :  6.86 MA(20) :  6.82
MA(100) :  6.69 MA(250) :  6.79
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  31.5 D(3) :  46.4
RSI RSI(14): 43.3
52-week High :  8.94 Low :  4.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PROF ] has closed above bottom band by 1.3%. Bollinger Bands are 3.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.69 - 6.76 6.76 - 6.8
Low: 6.16 - 6.24 6.24 - 6.29
Close: 6.29 - 6.42 6.42 - 6.5
Company Description

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Headline News

Sat, 21 Nov 2026
Is Profound Medical (NASDAQ:PROF) Worth A Closer Look Now? - Kalkine Media

Wed, 11 Nov 2026
Profound Medical (NasdaqCM:PROF) Stock Forecast & Analyst Predictions - Simply Wall St

Fri, 06 Nov 2026
What Profound Medical (PROF) Said on Its Q3 Earnings Call - Yahoo Finance

Mon, 02 Nov 2026
Profound Medical expands U.S. sales network through Cook Medical partnership (PROF:NASDAQ) - Seeking Alpha

Fri, 09 Oct 2026
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength? - Yahoo Finance

Fri, 09 Oct 2026
Profound Medical: Q3 Revenue Beats Outlook (Rating Upgrade) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 37 (M)
Shares Float 36 (M)
Held by Insiders 4 (%)
Held by Institutions 45.4 (%)
Shares Short 1,560 (K)
Shares Short P.Month 1,570 (K)
Stock Financials
EPS -1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.83
Profit Margin -171.6 %
Operating Margin -445.7 %
Return on Assets (ttm) -39.5 %
Return on Equity (ttm) -73.6 %
Qtrly Rev. Growth 12.3 %
Gross Profit (p.s.) 0.37
Sales Per Share 0.52
EBITDA (p.s.) -0.96
Qtrly Earnings Growth 0 %
Operating Cash Flow -36 (M)
Levered Free Cash Flow -25 (M)
Stock Valuations
PE Ratio -6.45
PEG Ratio 0
Price to Book value 3.48
Price to Sales 12.24
Price to Cash Flow -6.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

Stoxline iOS

Alpha Bridge iOS

OptionCalc iOS

StockChart Android

Stoxline Android

Alpha Bridge Android

OptionCalc Android